Joel A. Wirth

1.6k total citations
26 papers, 1.2k citations indexed

About

Joel A. Wirth is a scholar working on Pulmonary and Respiratory Medicine, Cardiology and Cardiovascular Medicine and Genetics. According to data from OpenAlex, Joel A. Wirth has authored 26 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Pulmonary and Respiratory Medicine, 9 papers in Cardiology and Cardiovascular Medicine and 5 papers in Genetics. Recurrent topics in Joel A. Wirth's work include Pulmonary Hypertension Research and Treatments (13 papers), Vascular Anomalies and Treatments (5 papers) and Tracheal and airway disorders (3 papers). Joel A. Wirth is often cited by papers focused on Pulmonary Hypertension Research and Treatments (13 papers), Vascular Anomalies and Treatments (5 papers) and Tracheal and airway disorders (3 papers). Joel A. Wirth collaborates with scholars based in United States, Romania and Canada. Joel A. Wirth's co-authors include Robert I. White, Jeffrey Pollak, William M. Bement, Tama Hasson, Richard E. Cheney, Mark S. Mooseker, Silvio E. Inzucchi, Inaam A. Nakchbandi, Daniel W. Lee and Kevin W. Dickey and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Gastroenterology and Journal of Cell Science.

In The Last Decade

Joel A. Wirth

22 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Joel A. Wirth United States 12 831 597 248 182 152 26 1.2k
Megan E. Begbie Canada 10 254 0.3× 299 0.5× 24 0.1× 88 0.5× 109 0.7× 11 580
Matthieu Canuet France 15 665 0.8× 117 0.2× 216 0.9× 130 0.7× 97 0.6× 48 934
Azza Abdel Gawad Tantawy Egypt 17 106 0.1× 307 0.5× 48 0.2× 171 0.9× 58 0.4× 75 858
Niti Dham United States 14 86 0.1× 543 0.9× 138 0.6× 89 0.5× 60 0.4× 31 750
Yuval Bdolah Israel 18 142 0.2× 65 0.1× 167 0.7× 304 1.7× 111 0.7× 29 2.8k
Gillian Lowe United Kingdom 17 115 0.1× 189 0.3× 189 0.8× 119 0.7× 70 0.5× 44 965
Judith K. Sato United States 16 310 0.4× 188 0.3× 56 0.2× 229 1.3× 127 0.8× 28 803
Ashima Gulati India 21 200 0.2× 213 0.4× 19 0.1× 400 2.2× 128 0.8× 45 1.4k
Imran Ahmad Canada 15 74 0.1× 122 0.2× 389 1.6× 323 1.8× 85 0.6× 92 1.1k
Katsushi Kurosu Japan 16 575 0.7× 72 0.1× 102 0.4× 163 0.9× 96 0.6× 53 1.0k

Countries citing papers authored by Joel A. Wirth

Since Specialization
Citations

This map shows the geographic impact of Joel A. Wirth's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joel A. Wirth with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joel A. Wirth more than expected).

Fields of papers citing papers by Joel A. Wirth

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joel A. Wirth. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joel A. Wirth. The network helps show where Joel A. Wirth may publish in the future.

Co-authorship network of co-authors of Joel A. Wirth

This figure shows the co-authorship network connecting the top 25 collaborators of Joel A. Wirth. A scholar is included among the top collaborators of Joel A. Wirth based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joel A. Wirth. Joel A. Wirth is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Gagnon, David J., Sergey Ryzhov, Meghan May, et al.. (2022). Ceftriaxone to PRevent pneumOnia and inflammaTion aftEr Cardiac arresT (PROTECT): study protocol for a randomized, placebo-controlled trial. Trials. 23(1). 197–197. 3 indexed citations
3.
Cohen, Mylan C., et al.. (2019). Pulmonary hypertension subjects exhibit right ventricular transient exertional dilation during supine exercise stress echocardiography. Pulmonary Circulation. 9(2). 1–10. 8 indexed citations
4.
Gray, Michael P., et al.. (2018). Update on the PHA Pulmonary Hypertension Care Center Network: Early Experience With the National Accreditation Program. Advances in Pulmonary Hypertension. 16(4). 179–184. 4 indexed citations
5.
Wirth, Joel A., et al.. (2017). What Is the Role of Oral Prostacyclin Pathway Medications in Pulmonary Arterial Hypertension Management?. Current Hypertension Reports. 19(12). 97–97. 8 indexed citations
6.
Ryan, Michael J., et al.. (2017). A systematic review of transition studies of pulmonary arterial hypertension specific medications. Pulmonary Circulation. 7(2). 326–338. 19 indexed citations
7.
Chakinala, Murali M., et al.. (2016). Managing the Patient with Pulmonary Hypertension. Cardiology Clinics. 34(3). 489–500. 11 indexed citations
8.
9.
Smith, Kathryn, et al.. (2012). Evaluation of a Clinical Protocol Using Tenecteplase for Acute Massive Pulmonary Embolism. CHEST Journal. 142(4). 819A–819A. 1 indexed citations
10.
Gordon, Fredric D., et al.. (2010). Successful outcomes following living donor liver transplantation for portopulmonary hypertension. Liver Transplantation. 16(8). 983–989. 29 indexed citations
11.
Wirth, Joel A., et al.. (2008). [The influence of nCPAP therapy on the autonomic nervous system dysfunction in OSA patients].. PubMed. 111(2). 379–82.
12.
Holm, Carole, et al.. (2001). Influence of Gender on Rates of Hospitalization, Hospital Course, and Hypercapnea in High-Risk Patients Admitted for Asthma. CHEST Journal. 119(1). 115–119. 60 indexed citations
13.
Nakchbandi, Inaam A., Silvio E. Inzucchi, & Joel A. Wirth. (2000). Primary Pulmonary Hypertension and Thyroid Disease. CHEST Journal. 118(4). 1224–1225. 2 indexed citations
14.
Faughnan, Marie E., Yvonne W. Lui, Joel A. Wirth, et al.. (2000). Diffuse Pulmonary Arteriovenous Malformations. CHEST Journal. 117(1). 31–38. 123 indexed citations
15.
Nakchbandi, Inaam A., Joel A. Wirth, & Silvio E. Inzucchi. (1999). Pulmonary Hypertension Caused by Graves’ Thyrotoxicosis. CHEST Journal. 116(5). 1483–1485. 73 indexed citations
16.
Lee, Daniel W., Robert I. White, T K Egglin, et al.. (1997). Embolotherapy of Large Pulmonary Arteriovenous Malformations: Long-Term Results. The Annals of Thoracic Surgery. 64(4). 930–940. 220 indexed citations
17.
Redlich, Carrie A., Robert Homer, Brian R. Smith, Joel A. Wirth, & Mark R. Cullen. (1996). Immunologic Responses to Isocyanates in Sensitized Asthmatic Subjects. CHEST Journal. 109(3). 6S–8S. 11 indexed citations
18.
Wirth, Joel A., et al.. (1996). Human myosin-IXb, an unconventional myosin with a chimerin-like rho/rac GTPase-activating protein domain in its tail. Journal of Cell Science. 109(3). 653–661. 84 indexed citations
19.
Redlich, Carrie A., Ariëtte M. van Bennekum, Joel A. Wirth, et al.. (1995). Vitamin A Chemoprevention of Lung Cancer. Advances in experimental medicine and biology. 375. 17–29.
20.
Mette, Stephen A., Harold I. Palevsky, Giuseppe G. Pietra, et al.. (1992). Primary Pulmonary Hypertension in Association with Human Immunodeficiency Virus Infection: A Possible Viral Etiology for Some Forms of Hypertensive Pulmonary Arteriopathy. American Review of Respiratory Disease. 145(5). 1196–1200. 146 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Megan E. Begbie Breakdown of academic impact, for papers by Matthieu Canuet Breakdown of academic impact, for papers by Azza Abdel Gawad Tantawy Breakdown of academic impact, for papers by Niti Dham Breakdown of academic impact, for papers by Yuval Bdolah Breakdown of academic impact, for papers by Gillian Lowe Breakdown of academic impact, for papers by Judith K. Sato Breakdown of academic impact, for papers by Ashima Gulati Breakdown of academic impact, for papers by Imran Ahmad Breakdown of academic impact, for papers by Katsushi Kurosu
Rankless by CCL
2026